Online citations, reference lists, and bibliographies.
← Back to Search

Continuing Medical Education (Therapy)

C. Ellis, J. Voorhees
Published 1987 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Etretinate is a retinoid given orally for the treatment of psoriasis and many other dermatoses. Side effects are similar to the hypervitaminosis A condition. Etretinate represents a substantial advance in dermatologic therapy. (J Am Acad Dermatol 1987;16:267-91.)
This paper references
10.1016/S0190-9622(83)70184-2
Retinoid therapy is associated with excess granulation tissue responses.
J. P. Campbell (1983)
10.1016/S0190-9622(83)70203-3
Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis.
H. Wolska (1983)
10.2165/00003088-198510010-00002
Clinical Pharmacokinetics of the Retinoids
R. Lucek (1985)
10.1111/1523-1747.EP12533435
Decreased urinary polyamines in patients with psoriasis treated with etretinate.
R. Grekin (1983)
10.1001/ARCHDERM.1983.01650270005006
Toxic effects of the aromatic retinoid etretinate.
B. Fontan (1983)
Palmoplantar eruption associated with etretinate therapy.
M. David (1986)
10.1056/NEJM198005083021919
Oral retinoid treatment of human papillomavirus type 5-induced epidermodysplasia verruciformis.
M. Lutzner (1980)
10.1111/J.1600-0714.1983.TB00359.X
Severe oral lichen planus: remission and maintenance with vitamin A analogues.
K. Sloberg (1983)
10.1159/000249872
A randomized trial of etretinate (Tigason) in palmoplantar pustulosis.
E. Foged (1983)
10.1159/000429405
Retinoic Acid in Recessive Dystrophic Epidermolysis bullosa
T. Cooper (1985)
10.1111/j.1365-2133.1981.tb01709.x
Ultrastructural evidence suggesting an immunomodulatory activity of oral retinoid
D. Tsambaos (1981)
10.1016/S0190-9622(86)70009-1
Combination therapy for psoriasis with methotrexate and etretinate.
E. Tuyp (1986)
Retinoid dermatitis mimicking progression in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group.
L. Molin (1985)
10.1111/j.1365-4362.1984.tb05670.x
Impaired Motility and Random Migration of Viatl Polymorphonuclears in Vitro after therapy with Oral Aromatic Retionoid in Psoriasis
R. Bauer (1984)
10.1016/S0140-6736(83)91394-6
VITAMIN A AND RETINOIDS: FROM NUTRITION TO PHARMACOTHERAPY IN DERMATOLOGY AND ONCOLOGY
W. Bollag (1983)
10.1016/S0140-6736(84)91526-5
IMPAIRED RENAL FUNCTION AND HYPERCALCAEMIA ASSOCIATED WITH ETRETINATE
F. Horber (1984)
10.1001/ARCHDERM.1984.01650370110022
Hepatotoxic reactions in a patient treated with etretinate.
V. Weiss (1984)
10.1001/ARCHDERM.1983.01650330038011
Antipsoriatic activity of a new synthetic retinoid. The arotinoid RO 13-6298.
D. Tsambaos (1983)
10.1016/S0140-6736(80)92363-6
SYNTHETIC RETINOIDS FOR ACNE
R. Mackie (1980)
10.1111/j.1365-2133.1984.tb07470.x
A randomized double‐blind comparison of PUVA‐etretinate and PUVA‐placebo in the treatment of chronic plaque psoriasis
S. Parker (1984)
10.1159/000249438
Ichtyose linéaire circonflexe de Comèl: traitement par Ro 10-9359
C. Mathys (1985)
[Combined retinoid and UV-phototherapy in pustulosis subcornealis (Sneddon-Wilkinson)].
D. Lubach (1980)
10.1016/S0140-6736(83)90495-6
INTRACRANIAL HYPERTENSION WITH ETRETINATE
J. M. Bonnetblanc (1983)
Treatment of localized scleroderma and lichen sclerosus with etretinate.
J. Neuhofer (1984)
10.1016/S0378-4347(00)83330-7
Analysis of retinoids by high-performance liquid chromatography using programmed gradient separation.
T. Annesley (1984)
10.1159/000250382
Oral retinoid (Ro 10-9359) in children with lamellar ichthyosis, epidermolytic hyperkeratosis and symmetrical progressive erythrokeratoderma.
L. Tamayo (1980)
10.1016/S0190-9622(84)70271-4
Excess granulation tissue during etretinate therapy.
E. Hodak (1984)
Chronic cutaneous arsenism treated with aromatic retinoid.
M. Thianprasit (1984)
10.1016/S0140-6736(82)91393-9
ETRETINATE IN TREATMENT OF ACTINIC KERATOSIS: A Double-blind Crossover Study
M. Moriarty (1982)
10.1016/S0190-9622(83)80143-1
The development of retinoids in experimental and clinical oncology and dermatology.
W. Bollag (1983)
10.1016/S0190-9622(84)80329-1
Isotretinoin therapy is associated with early skeletal radiographic changes.
C. Ellis (1984)
Serum vitamin A and E levels in patients with lichen sclerosus and carcinoma of the vulva--effect of oral etretinate treatment.
U. Romppanen (1985)
10.1007/BF00349083
Ro 15-1570, a new sulfur-containing retinoid devoid of bone toxicity in rats
A. Kistler (1984)
10.1111/j.1365-2133.1980.tb05694.x
Treatment of disseminated superficial actinic porokeratosis with a new aromatic retinoid (Ro 10‐9359)
A. L. Kariniemi (1980)
10.1111/J.1365-2133.1981.TB00760.X
An unusual adverse reaction to Ro 10‐9359
K. Moulopoulou-Karakitsou (1981)
10.1001/ARCHDERM.1981.01650030038018
Retinoids, cancer, and the skin.
P. Elias (1981)
10.1001/ARCHDERM.1981.01650100013019
Nature of skin fragility in patients receiving retinoids for systemic effect.
M. Williams (1981)
[Pachydermia of the larynx--treatment with aromatic retinoid (Ro10-9359). Further results].
E. Bichler (1982)
Retinoid dermatitis mimicking "eczéma craquelé".
A. Taïeb (1985)
10.1111/j.1365-4362.1985.tb05461.x
Etretinate Improves Localized Porokeratosis of Mibelli
J. P. Campbell (1985)
Hyperkeratosis lenticularis perstans (Flegel's disease).
K. Kuokkanen (1983)
10.1016/0006-2952(85)90623-9
Effects of retinoids on growth and dissemination of malignant tumours: immunological considerations.
S. Eccles (1985)
10.1111/J.1365-2125.1984.TB02499.X
The effect of etretinate on the cyclo-oxygenase and lipoxygenase products of arachidonic acid metabolism in psoriatic skin.
E. Wong (1984)
10.1056/NEJM198404193101605
Vitamin A and retinoids in health and disease.
D. S. Goodman (1984)
Retinoid acid in the treatment of hyperkeratosis lenticularis perstans Flegel.
H. Lindemayr (1982)
10.1016/S0190-9622(85)80401-1
Etretinate (Tigason, Europe; Tegison, USA) in psoriasis: advantages of low doses progressively increased.
L. Dubertret (1985)
Donor organs: Mr. Dalyell's bill.
R. Deitch (1979)
Treatment of cutaneous lupus erythematosus with etretinate.
T. Ruzicka (1985)
10.1159/000250503
Treatment with an oral aromatic retinoid in linear porokeratosis.
H. Pehamberger (1980)
10.1016/S0190-9622(84)80157-7
Acrodermatitis continua of Hallopeau: treatment with etretinate and review of relapsing pustular eruptions of the hands and feet.
L. Pearson (1984)
10.1056/NEJM197902153000701
Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid.
G. Peck (1979)
10.1159/000250532
A case of centrolobular toxic necrosis of the liver due to aromatic retinoid--Tigason (Ro 10-9359).
P. Thune (1980)
10.1111/J.1365-2133.1985.TB04867.X
Erythroderma due to etretinate
J. Levin (1985)
10.1001/ARCHDERM.1983.01650340003007
Concurrent methotrexate and etretinate therapy for psoriasis.
J. D. Adams (1983)
10.1001/ARCHDERM.1984.01650450118033
Confluent and reticulated papillomatosis successfully treated with the aromatic etretinate.
C. Bruynzeel-Koomen (1984)
10.1016/S0190-9622(82)70058-1
International studies of the efficacy of etretinate in the treatment of psoriasis.
C. Ehmann (1982)
10.1001/ARCHDERM.1987.01660280073026
Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate.
C. Ellis (1987)
10.1159/000249426
Effect of oral retinoid treatment on human natural killer cell activity.
C. Jansén (1985)
Mutilating palmoplantar keratoderma successfully treated with etretinate.
K. Wereide (1984)
10.1159/000250124
Side effects due to RO 10-9359 (Tigason). A retrospective study.
E. Foged (1982)
10.1111/j.1365-2230.1985.tb00541.x
Clinical use of vitamin A and its derivatives– physiological and pharmacological aspects *
A. Vahlquist (1985)
Epithelial cell proliferation of oral lichen planus in patients treated with an aromatic retinoid.
H. Schell (1983)
[Tumor prevention in xeroderma pigmentosum using aromatic retinoid (Ro 10-9359)].
O. Braun-Falco (1982)
10.1007/978-3-642-68023-6_36
Comparative Analysis of Two Retinoids in the Treatment of Disorders of Keratinization
G. Peck (1981)
10.1111/j.1365-2133.1980.tb05692.x
Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10‐9359)
A. Lassus (1980)
Acquired pili torti in two patients treated with synthetic retinoids.
S. Hays (1985)
Retinoids as chemopreventive and anticancer agents intact animals (review).
Hill Dl (1982)
10.1001/ARCHDERM.1982.01650200003002
Soft nails after treatment with aromatic retinoids.
R. Lindskov (1982)
10.1016/S0140-6736(82)92623-X
DEGREE OF BRONCHIAL METAPLASIA IN HEAVY SMOKERS AND ITS REGRESSION AFTER TREATMENT WITH A RETINOID
J. Gouveia (1982)
A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically.
Polano Mk (1982)
10.2165/00003495-198326010-00002
Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.
A. Ward (1983)
[Aromatic retinoid--oral photochemotherapy in chronic vegetating pyoderma].
A. Krebs (1985)
10.1055/S-2008-1068402
[Embryonal malformation following etretinate therapy of Darier's disease in the mother].
H. Kietzmann (1986)
A rosacea-like eruption induced by Tigason (Ro 10-9359) treatment.
E. Crivellato (1982)
10.1111/j.1365-2133.1980.tb05693.x
Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: a double‐blind trial
H. Rhee (1980)
10.1111/j.1365-2133.1983.tb11627.x
(19) Arsenical keratoses‐response to etretinate and electron beam therapy
P. Coburn (1983)
10.1159/000249322
Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis.
M. Gilbert (1986)
10.1001/ARCHDERM.1982.01650140029013
Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients.
G. Mahrle (1982)
[Acantholysis and eosinophilic spongiosis: pemphigus herpetiformis. Successful retinoid therapy].
R. Bauer (1983)
Poussée évolutive d'une hyperostose vertébrale ankylosante induite par un rétinoïde
P. Bennet (1985)
10.1016/S0190-9622(86)80341-3
Drug eruption from trazodone.
F. Rongioletti (1986)
Peroral aromatic retinoid treatment of palmoplantar pustulosis: double-blind comparison of Ro 10-9359 and placebo.
C. Jansen (1979)
10.1016/S0190-9622(83)80125-X
Retinoid therapy of recessive dystrophic epidermolysis bullosa.
P. Fritsch (1983)
10.1016/S0190-9622(84)70204-0
Retinoids: a review.
C. Dicken (1984)
10.1111/j.1365-2133.1983.tb11625.x
(17) Bullous ichthyosiform erythroderma treated with etretinate
C. Zachary (1983)
Etretinate, lomustine, and bleomycin versus lomustine and bleomycin in advanced squamous cell lung carcinoma.
W. Weber (1983)
10.1111/J.1524-4725.1984.TB01181.X
Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome.
M. Cristofolini (1984)
10.1159/000429442
Liver Biopsy during Etretinate (Tigason®) Treatment
H. Zachariae (1985)
10.1111/j.1365-2133.1985.tb02382.x
Etretinate in pustular psoriasis of plams and soles
S. White (1985)
10.1002/j.1552-4604.1985.tb02881.x
Effect of Meals on the Kinetics of Etretinate
W. Colburn (1985)
[The Papillon-Lefevre syndrome (keratosis palmoplantaris with periodontopathy). Treatment with etretinate].
W. Wehrmann (1985)
10.1111/j.1365-2133.1985.tb02293.x
A sequential comparison of etretinate (Tigason®) and isotretinoin (Roaccutane®) with special regard to their effects on serum lipoproteins
C. Vahlquist (1985)
Reiter's disease: successful treatment of the skin manifestations with oral etretinate.
D. Benoldi (1984)
10.1159/000249942
Etretinate (Tigason) and betamethasone valerate (Celeston valerate) in the treatment of psoriasis. A double-blind, randomized, multicenter trial.
J. V. Christiansen (1982)
10.1001/ARCHDERM.1978.01640200065017
Oral treatment of keratosis follicularis with a new aromatic retinoid.
C. Orfanos (1978)
10.1016/S0140-6736(81)91370-2
ETRETINATE IN BOWENOID PAPULOSIS
C. Blanchet-Bardon (1981)
10.1111/j.1365-2133.1985.tb02301.x
Controlled trials of PUVA and etretinate for psoriasis
M. Corbett (1985)
10.1111/j.1365-2133.1981.tb00753.x
Severe disorders of keratinization: effects of treatment with Tigason (etretinate)
R. Marks (1981)
Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides.
H. Zachariae (1982)
10.1159/000249351
Keratoderma climactericum (Haxthausen's disease): clinical signs, laboratory findings and etretinate treatment in 10 patients.
P. Deschamps (1986)
10.1111/j.1365-2133.1985.tb15267.x
A case of eruptive keratoacanthoma treated by oral etretinate
K. Yoshikawa (1985)
10.1177/028418518502600205
Radiography of the Spine and Sacro-Iliac Joints in Ankylosing Spondylitis and Psoriasis
K. Dale (1985)
10.1016/S0140-6736(83)91994-3
ADDITION OF RETINOIDS TO PUVA FOR PSORIASIS
C. Lawrence (1983)
10.1001/ARCHOPHT.1986.01050130079024
Abnormal retinal function associated with fenretinide, a synthetic retinoid.
M. Kaiser-Kupfer (1986)
10.1016/S0190-9622(85)70086-2
The role of etretinate (Tegison; Tigason) in the management of keratoacanthoma.
M. Cristofolini (1985)
10.1016/S0190-9622(85)70008-4
Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis.
N. Väätäinen (1985)
10.1016/S0190-9622(84)70097-1
Vertebral abnormalities associated with synthetic retinoid use.
L. Gerber (1984)
Excessive cerumen production due to the aromatic retinoid Tigason in a patient with Darier's disease.
M. Kramer (1982)
10.1016/S0190-9622(85)70141-7
Etretinate: management of keratoma hereditaria mutilans in four family members.
J. Rivers (1985)
10.1111/1523-1747.EP12533424
Effects of retinoid (Ro 10-9359) on the plasma membrane of keratinocytes in patients with psoriasis: a freeze-fracture analysis.
Y. Kitajima (1983)
10.1111/1523-1747.EP12522564
Effect of etretinate on chemotaxis of neutrophils from patients with pustular and vulgar psoriasis.
P. Pigatto (1983)
10.1001/ARCHDERM.1983.01650320001002
Response of psoriatic nails to the aromatic retinoid etretinate.
H. Rabinovitz (1983)
10.1016/0090-8258(81)90086-X
Chemoprevention of Cancer with Retinoids.
G. Peck (1981)
10.1159/000250514
Disseminated porokeratosis Mibelli treated with RO 10-9359. A study of two cases with ultrastructural remarks.
S. Bundino (1980)
10.1016/S0190-9622(86)70300-9
Premature epiphyseal closure--a complication of etretinate therapy in children.
J. Prendiville (1986)
10.1016/S0190-9622(83)70012-5
Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses.
R. Kaplan (1983)
10.1111/j.1365-2133.1983.tb03991.x
Treatment of cutaneous lymphoma with etretinate
A. Claudy (1983)
10.1159/000410143
Current developments of oral retinoid therapy with three generations of drugs. Non-aromatic, monoaromatic and polyaromatic retinoids (arotinoids).
C. Orfanos (1985)
10.1111/j.1365-2230.1983.tb01741.x
Treatment of extensive virus warts with etretinate (Tigason) in a patient with sarcoidosis
J. Boyle (1983)
10.1159/000249896
[Aromatic retinoid--oral photochemotherapy (RePUVA) for actinic reticuloid].
T. Hunziker (1983)
10.1159/000429440
Retinoids: Effect on the Liver
H. Roenigk (1985)
10.1159/000249773
Treatment of generalized pustular psoriasis with Ro-10-9359.
T. Lóránd (1983)
10.1111/j.1365-2133.1976.tb15541.x
Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis
C. Orfanos (1976)
10.1159/000249664
Etretinate (Tigason) hepatitis in 2 patients.
P. C. van Voorst Vader (1984)
[Systemic retinoid therapy with etretinate in pachyonychia congenita].
E. Hoting (1985)
Ro 10-9359, an aromatic retinoid in the treatment of psoriatic arthritis. Clinical and immunological studies.
M. Rosenthal (1982)
10.1001/ARCHDERM.1986.01660180029009
Etretinate therapy and immune activities.
S. Kang (1986)
10.1159/000249724
Unusual cases of Meleda keratoderma treated with aromatic retinoid etretinate.
L. Brambilla (1984)
Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis.
C. Orfanos (1979)
10.1093/JNCI/73.6.1423
Epidemiology of retinoids and cancer.
S. Graham (1984)
10.1001/ARCHDERM.1984.01650480017004
Methotrexate and etretinate in the treatment of psoriasis.
E. Vanderveen (1984)
10.1159/000250880
Tissue changes in psoriatic plaques after oral administration of retinoid.
C. Orfanos (1978)
10.1001/ARCHDERM.1982.01650210040015
Methotrexate and etretinate as concurrent therapies in severe psoriasis.
E. Vanderveen (1982)
10.1111/J.1365-2133.1982.TB00938.X
Oedema, a rare adverse reaction to etretinate(Tigason)
J. Lauharanta (1982)
10.1016/S0190-9622(85)70186-7
Etretinate therapy reduces polymorphonuclear leukocyte chemotaxis-enhancing properties of psoriatic serum.
C. Ellis (1985)
[Development outbreak of ankylosing vertebral hyperostosis induced by a retinoid].
P. Bennet (1985)
10.1159/000249833
Effect of oral aromatic retinoid (Ro 10-9359) on human papilloma virus-2-induced common warts.
G. Gross (1983)
[Generalized ichthyosis associated with a spastic syndrome of the lower limbs, a variant of Sjögren-Larsson syndrome? Light and electron microscopy study of ichthyosis and its evolution with oral etretinate treatment].
L. Lahmar (1984)
10.1111/j.1365-2133.1985.tb02294.x
Serial liver biopsies in psoriatic patients receiving long‐term etretinate
H. Roenigk (1985)
10.1016/S0190-9622(84)80331-X
Multiple persistent keratoacanthomas: treatment with oral etretinate.
D. Benoldi (1984)
10.1111/j.1365-2133.1985.tb02085.x
Pharmacology and Treatment Maintenance treatment of psoriasis by Tigason: a double‐blind randomized clinical trial
L. Dubertret (1985)
10.1111/J.1365-2133.1985.TB02302.X
Retinoids and PUVA in psoriasis.
K. Wolff (1984)
10.1159/000249755
Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.
H. Beck (1983)
10.1136/ard.44.3.189
A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis.
R. Hopkins (1985)
10.1136/bmj.1.4396.484-c
Care of the Feet
Dewhurst Cj (1945)
10.1111/j.1365-2230.1985.tb00605.x
Retinoid‐induced skin fragility in a patient with hepatic disease
V. Neild (1985)
10.1016/S0190-9622(85)80367-4
Benign intracranial hypertension during etretinate therapy for mycosis fungoides.
R. Viraben (1985)
10.1111/j.1365-2133.1983.tb04618.x
Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate *
O. Rollman (1983)
[Positive effect of etretinate (RO 10-9359) in a case of familial benign pemphigus].
J. Bonafé (1983)
10.1111/j.1365-2133.1983.tb04005.x
Retinoids and the gastric mucosa
P. V. Harrison (1983)
10.1111/j.1365-2133.1985.tb02320.x
The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis
A. Lassus (1985)
10.1111/j.1365-2133.1982.tb00904.x
Severe oral lichen planus: treatment with an aromatic retinoid (etretinate)
K. Hersle (1982)
10.1016/S0190-9622(85)80141-9
Short-term etretinate for pustular psoriasis.
M. G. Rubin (1985)
10.1055/S-2008-1069820
[Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
G. Mahrle (1983)
10.1111/1523-1747.EP12261476
Etretinate: effect of milk intake on absorption.
J. DiGiovanna (1984)
10.1111/j.1365-2230.1985.tb00599.x
Acquired kinking of the hair associated with etretinate therapy
R. Graham (1985)
10.1111/j.1365-4362.1985.tb05459.x
Etretinate in the Treatment of Disseminated Porokeratosis of Mibelli
S. Hacham-Zadeh (1985)
10.1159/000249700
Motretinide versus benzoyl peroxide in the treatment of acne vulgaris.
A. Lassus (1984)
10.1111/j.1365-2133.1980.tb01662.x
Therapeutic evaluation of the oral retinoid Ro 10‐9359 in several non‐psoriatic dermatoses
Pablo A.Viglioglia (1980)
10.1016/S0190-9622(85)80334-0
Oral isotretinoin followed by psoralens and ultraviolet A or ultraviolet B for psoriasis.
R. Roenigk (1985)
10.1159/000250256
Ro 11-1430, a new retinoic acid derivative for the topical treatment of acne.
K. Nordin (1981)
10.1016/0030-4220(84)90054-9
The treatment of erosive lichen planus with a retinoid--etretinate.
M. Ferguson (1984)
10.1016/S0190-9622(86)70110-2
Increased muscle tone during etretinate therapy.
C. Ellis (1986)
[Clinico-therapeutic index and dosimetry of oral treatment with aromatic retinoid. A comparison of different dosages].
H. Gollnick (1983)
EMERGENCY HYPOTHERMIC IN MENINGOCOCCAL MENINGITIS.
P. Véghelyi (1965)
Treatment of arsenical keratosis with etretinate.
S. Sc (1983)
10.1159/000429443
Hepatologic Side Effects during Long-Term Retinoid Therapy: Ito Cells and Portal Hypertension
P. C. V. V. Vader (1985)
Differential hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmoplantar psoriasis.
A. Vahlquist (1985)
10.1016/S0190-9622(84)80007-9
Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate.
M. M. Rosenbaum (1984)
10.1056/NEJM198611063151901
Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate.
J. DiGiovanna (1986)
Vitamin A transport complex during treatment with an oral aromatic retinoid (RO 10-9359).
J. Lauharanta (1981)
10.1016/S0140-6736(85)92344-X
MALFORMATION OF FETUS CONCEIVED 4 MONTHS AFTER TERMINATION OF MATERNAL ETRETINATE TREATMENT
W. Grote (1985)
OYSTER AND VIRUS.
Simpson Ca (1964)
Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience.
C. Orfanos (1983)
10.1001/ARCHDERM.1984.01650450100030
Ichthyosis hystrix (Curth-Macklin). Light and electron microscopic studies performed before and after etretinate treatment.
L. Kanerva (1984)
10.1159/000249441
Etretinate therapy in generalized pustular psoriasis (Zumbusch type). Immediate and long-term results.
H. Wolska (1985)
10.1042/BJ1710711
Determination of binding affinities of retinoids to retinoic acid-binding protein and serum albumin.
B. Sani (1978)
10.1016/S0140-6736(85)92546-2
DIFFUSE HYPEROSTOSIS ASSOCIATED WITH ETRETINATE
S. Burge (1985)
10.1038/bjc.1985.62
British Association For Cancer Research Workshop on the Potential Clinical Use of Retinoids in Oncology
G. Rustin (1985)
10.1016/S0190-9622(84)80343-6
Treatment of hyperkeratotic conditions of the legs with etretinate.
J. English (1984)
Maladie de Cowden: efficacité de l'étrétinate sur les manifestations cutanées et digestives
J. Thivolet (1984)
[Comparison of RePUVA and aromatic retinoid Ro 10-9359 with methotrexate in severe forms of psoriasis].
Mashkilleysson Al (1983)
10.1111/j.1365-2230.1983.tb01799.x
Monilethrix treated with the oral retinoid Ro 10‐9359 (Tigason)
L. Tamayo (1983)
Treatment of erythrokeratodermia variabilis with oral synthetic retinoids.
Fixler Zc (1980)
10.1159/000249746
Pilot study of a new retinoid, Ro 12-7554, in psoriasis and in some congenital disorders of keratinization.
F. Ott (1983)
10.1111/j.1365-2133.1982.tb00528.x
Inhibition of neutrophil migration by etretinate and its main metabolite
L. Dubertret (1982)
10.1111/j.1365-2133.1984.tb07471.x
A comparison of PUVA‐etretinate and PUVA‐placebo for palmoplantar pustular psoriasis
C. Lawrence (1984)
10.1001/ARCHDERM.1985.01660070067017
Etretinate therapy for psoriasis. Reduction of antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes.
C. Ellis (1985)
10.1111/J.1365-2133.1983.TB11613.X
(5) Melkersson‐Rosenthal syndrome
J. Cream (1983)
Abortions because of unavailability of prenatal diagnosis.
H. Eb (1981)
10.1001/ARCHDERM.1981.01650070046024
Oral retinoids. Broad-spectrum dermatologic therapy for the 1980s.
J. Voorhees (1981)
10.1016/0014-2999(84)90109-2
Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro.
M. Bray (1984)
10.1111/J.1365-2230.1984.TB00858.X
A serious side‐effect of etretinate (Tigason®)
J. H. Smitt (1984)
10.1111/j.1365-2133.1985.tb15269.x
Chronic active hepatitis associated with etretinate therapy
V. Weiss (1985)
10.1016/S0022-5347(17)50192-5
Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland.
U. Studer (1984)
10.1111/j.1365-2133.1985.tb15268.x
Harlequin fetus successfully treated with etretinate
F. Lawlor (1985)
Naevomatose baso-cellulaire. Essai de prévention des transformations carcinomateuses par le rétöide aromatique.
Verret Jl (1982)
Treatment of psoriatic arthropathy with etretinate: a two-year follow-up.
G. Chieregato (1986)
10.1159/000474033
Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial.
O. Alfthan (1983)
Keratodermia punctata hereditaria treated with etretinate (Tigason).
Christiansen Jv (1983)
10.1111/j.1365-2133.1981.tb01206.x
The influence of Tigason’ (Ro 10–9359) on the serum lipoproteins in man
G. Michaëlsson (1981)
10.1159/000250023
Influence of retinoid Ro 10-9359 on cell-mediated immunity in vivo.
R. A. Fulton (1982)
10.1111/j.1365-2133.1983.tb01077.x
Ultrastructure of pityriasis rubra pilaris with observations during retinoid (etretinate) treatment
L. Kanerva (1983)
10.1016/S0190-9622(82)70059-3
Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase.
N. Lowe (1982)
10.1016/0277-5379(83)90196-7
The effects of a novel potent oral retinoid (Rol3-6298) in the treatment of multiple solar keratoses and squamous cell epithelioma.
T. Kingston (1983)



This paper is referenced by
10.1002/MDS.870030109
A new syndrome of axial muscle rigidity associated with etretinate therapy
R. Albin (1988)
10.1016/S1040-0486(97)80005-1
The spectrum of anogenital diseases in children
E. Siegfried (1997)
10.11340/SKINRESEARCH1959.37.68
A Case of Generalized Pustular Psoriasis
Noriko Yashiro (1995)
10.1016/S0083-6729(03)01013-6
Vitamin A and infancy. Biochemical, functional, and clinical aspects.
S. Perrotta (2003)
10.1111/j.1365-4362.1987.tb00578.x
Generalized Pustular Psoriasis
J. H. Lyons (1987)
10.1111/j.1365-4362.1989.tb02450.x
Noninfectious Causes of Fever and a Rash
W. Heymann (1989)
10.1016/S0190-9622(89)80158-6
Guttate psoriasis and vitiligo: anatomic cohabitation.
A. Menter (1989)
10.1007/BF00372013
Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid
P. Steijlen (2004)
10.1016/S0190-9622(08)81154-1
Peripheral neuropathy during etretinate therapy for psoriasis.
C. Hammer (1993)
10.1016/S0190-9622(98)70441-4
Pharmacokinetics of acitretin and etretinate.
U. W. Wiegand (1998)
10.1201/9780203912683.CH7
Cyclosporine in the Treatment of Severe Psoriasis
C. Ellis (2003)
10.1016/S0190-9622(88)70086-9
Acitretin improves psoriasis in a dose-dependent fashion.
M. T. Goldfarb (1988)
10.1111/j.1365-2133.1990.tb02891.x
Risk:benefit ratio in the treatment of psoriasis with systemic retinoids
B. Halioua (1990)
10.1111/j.1365-2133.1996.tb15661.x
Oral retinoids—efficacy and toxicity in psoriasis
H. Gollnick (1996)
10.1016/S0146-0005(97)80056-0
Vitamin A and its congeners.
M. Monga (1997)
10.1016/0190-9622(90)70317-B
Linear porokeratosis: successful treatment with diamond fraise dermabrasion.
P. Cohen (1990)
10.1016/0190-9622(92)70224-4
Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis.
T. Shiohara (1992)
10.1016/S0190-9622(08)81182-6
Efficacy of acitretin in severe cutaneous lichen planus.
P. Viglioglia (1990)
10.1016/S0733-8635(18)30632-6
New retinoids for dermatologic diseases. Uses and toxicity.
N. Lowe (1988)
10.3109/09546639009086719
Retinoids and the nails
R. Baran (1990)
PSORIASIS DEL CUERO CABELLUDO ALGUNOS ASPECTOS DEL TRATAMIENTO
S. R. Arosemena (1991)
10.1002/9781118286715.CH6
The Nail in Dermatological Disease
M. Holzberg (2012)
10.1016/S0190-9622(89)70138-9
Side-effect profile of acitretin therapy in psoriasis.
A. Gupta (1989)
10.2165/00002018-199309040-00006
Adverse Reactions to Oral Retinoids
C. Mills (1993)
10.1007/978-3-642-58483-1_15
Avian embryo as model for retinoid function in early development
Maija H. Zile (1999)
10.1016/S0213-9251(07)73119-2
Actualización en el uso del acitretino en la psoriasis
A. B. Garcia (2007)
10.1046/j.1365-2133.1996.d01-742.x
Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities
R. J. DOOREN‐GREEBE (1996)
10.1016/S0190-9622(88)70131-0
Long-term radiographic follow-up after isotretinoin therapy.
C. Ellis (1988)
10.1016/S0738-081X(01)00189-4
Hydroxy acids and retinoids in cosmetics.
M. Ramos-E-Silva (2001)
10.1016/S1040-0486(09)80019-7
Major adverse effects from systemic drugs: Defining the risks
S. E. Wolverton (1995)
10.1001/ARCHDERM.1996.03890310053007
Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris.
D. Margolis (1996)
10.1159/000029811
Effects of Systemic Treatment with Liarozole on Cutaneous Inflammation, Epidermal Proliferation and Differentiation in Extensive Plaque Psoriasis
J. V. Pelt (1998)
See more
Semantic Scholar Logo Some data provided by SemanticScholar